Analysis of the Effect of Gemcitabine Hydrochloride Combined with Cisplatin on the Level of Peripheral Blood Regulatory T Cells in Non-Small Cell Lung Cancer

  • Lanhong Ma
Keywords: Gemcitabine Hydrochloride, Cisplatin Therapy, Non-Small Cell Lung Cancer, T Cell Levels


The number of clinical patients with non-small cell lung cancer (NCLC) is increasing. The traditional treatment
is chemotherapy, and the commonly used treatment is gemcitabine hydrochloride combined with cisplatin. The
level of regulatory T cells in peripheral blood can effectively regulate the body's immune function, and has
important clinical significance for the clinical treatment of patients with NCLC. The purpose of this article is to
investigate the effect of gemcitabine hydrochloride combined with cisplatin on the level of regulatory T cells. 50
patients with NCLC admitted from January 2015 to December 2019 were selected. 50 cases (healthy control
group), a total of 100 cases. Among them, 44 males and 56 females, aged 26-78 years old, with an average of
(48.65±11.24) years old, the experimental group was treated with gemcitabine hydrochloride combined with
cisplatin to observe changes in T cell levels. The results of the study showed that before treatment, the T cell level
in the NCLC group was about 1.6%, and there was an increasing trend, while the control group fluctuated within
the range of 0.7-0.8 with little fluctuation; after treatment, the non-small cell level of T cells in the cell lung cancer
group decreased significantly, and by the ninth day it had dropped to about 0.8%. It can be seen that gemcitabine
hydrochloride combined with cisplatin can reduce the level of peripheral blood T cells in NCLC.